Oct 10, 2007 - Nektar Therapeutics (Nasdaq: NKTR) announced that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers... Nektar's Press Release-Oct 11, 2007
Nektar Therapeutics, NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors
Oct 10, 2007 - Nektar Therapeutics (Nasdaq: NKTR) announced that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers... Nektar's Press Release-
